ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$6.44 USD
-0.02 (-0.31%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $6.45 +0.01 (0.16%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ADMA 6.44 -0.02(-0.31%)
Will ADMA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADMA
Adma Biologics (ADMA) Stock Moves -0.31%: What You Should Know
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Other News for ADMA
Biotech Alert: Searches spiking for these stocks today
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Kaitlin Kestenberg Promoted to COO at ADMA Biologics
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price Target